From: Do we still need breast cancer screening in the era of targeted therapies and precision medicine?
 | Mortality reduction compared to 1975 (%) | Contribution to the difference in mortality reduction in 2012 versus 2000 (%) | |||||
---|---|---|---|---|---|---|---|
In 2000a | In 2012b | Difference | Screening advances | Chemotherapy advances | Hormone therapy advances | Trastuzumab | |
Overall | 37 | 49 | 12 | 17 | 38 | 29 | 15 |
ER+/HER2− | 39 | 51 | 12 | 19 | 39 | 42 | 0 |
ER+/HER2+ | 39 | 58 | 19 | 12 | 22 | 25 | 41 |
ER−/HER2+ | 29 | 45 | 16 | 11 | 32 | 0 | 57 |
ER−/HER2− | 29 | 37 | 8 | 22 | 78 | 0 | 0 |